Rare disease focus Orphalan specializes in orphan drugs and rare diseases, with recent expansion through the acquisition of Orphelia Pharma and ongoing partnerships to supply treatments in developing countries. Sales opportunity: target global rare disease networks, hospitals, and patient advocacy groups to expand access to Cuvrior and CuPrior portfolios.

Global partnerships Strategic collaborations with MAP International and the Wilson Disease Association to deliver Cuvrior in developing countries indicate appetite for international distribution and public-health programs. Sales opportunity: pursue co-promotion and distribution partnerships in low- and middle-income markets, leveraging MAP International’s network.

Recent expansion Acquisition of Orphelia Pharma signals scale-up in neurology and oncology for pediatric rare diseases, broadening product and geographic reach. Sales opportunity: align BD efforts with pediatric neurology and oncology centers, leveraging expanded portfolio to win new hospital and government tenders.

Product leadership Cuvrior and CuPrior launches position Orphalan as a provider of approved treatments for Wilson disease, with US and European commercialization milestones since 2022-2023. Sales opportunity: engage specialty pharmacies, liver and metabolic clinics, and genetics centers to drive uptake and adherence programs.

Moderate revenue scale Current revenue range of $25M-$50M and a 51-200 employee base indicate growing but focused operations with room for scalable partnerships. Sales opportunity: propose tiered partnership models, channel expansions, and white-label licensing to accelerate revenue growth while managing risk.